Search Results
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
well as collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM).Ivonescimab is currently being evaluated in more than 17 registrational Phase II/III studies, including seven global
More news about: Akeso, Inc.
Aug 12, 2026, 16:05 ET INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026Commercial preparations advancing in anticipation of potential product launch for INO-3107Positive
More news about: INOVIO Pharmaceuticals, Inc.
Aug 11, 2026, 08:49 ET AirCARE1 Secures FAA Authorization for Inhaled Nitric Oxide During Air Ambulance Transports
hypertension. In this population, iNO is FDA approved to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO). Continuing therapy during transport helps maintain oxygenation and pulmonary stability throughout the bedside-to-bedside journey.iNO may also support select burn
More news about: AirCARE1 Air Ambulance & Medical Escort Provider
Aug 04, 2026, 16:05 ET INOVIO to Report Second Quarter Financial Results on August 12, 2026
PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and
More news about: INOVIO Pharmaceuticals, Inc.
Jul 29, 2026, 20:53 ET INOVIO Announces Pricing of $20.0 Million Public Offering
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: Inovio Pharmaceuticals, Inc.
Jul 29, 2026, 16:01 ET INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: Inovio Pharmaceuticals, Inc.
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
ITI-1000 (PP65 DC vaccine), SURVAXM, OKN-007, BERUBICIN, GLIOVAC/SITOIGANAP, IGV-001, BGB-290, EO2401, VBI-1901, TEMFERON, NOX-A12 (OLAPTESED PEGOL), INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Lerapolturev, Rhenium (186RE) obisbemeda, and others.By 2036, among all the emerging therapies market sizes
More news about: DelveInsight Business Research, LLP
Jun 04, 2026, 16:37 ET Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: Kuehn Law, PLLC
May 28, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and
More news about: INOVIO Pharmaceuticals, Inc.
May 21, 2026, 16:05 ET Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
interventionsPLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: INOVIO Pharmaceuticals, Inc.
May 14, 2026, 06:39 ET Inolign étend ses services de trading en ligne à ses clients français
séparée des fonds. Son modèle en paliers, avec des comptes allant de Bronze à INO VIP, permet de modifier les conditions de service à mesure que les traders passent à des statuts de compte plus élevés.« La France fait partie
More news about: Inolign
May 13, 2026, 16:05 ET INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Record, specialty distributor, specialty pharmacy, and patient HUB.INO-5412In March 2026, INOVIO announced a clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 (INO-5401 plus INO-9012 in a single vial) in combination with cadonilimab, Akeso's first-in-class
More news about: INOVIO Pharmaceuticals, Inc.
May 08, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific Conferences
(Chicago)Poster Presentation: B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107Date: Saturday, May 30Time: 1:30 - 4:30 PM CDTAvailable abstracts will be shared on INOVIO's website following
More news about: INOVIO Pharmaceuticals, Inc.
Apr 07, 2026, 14:52 ET INO Deadline Today: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Apr 07, 2026, 09:00 ET INO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit -- The Gross Law Firm
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: The Gross Law Firm
Apr 06, 2026, 03:46 ET Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO
INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of INO during the class period listed are encouraged
More news about: DJS Law Group LLP
Apr 06, 2026, 02:44 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Apr 04, 2026, 07:19 ET INO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Apr 02, 2026, 18:19 ET INO Deadline: INO Investors with Losses in Excess of $100K Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Apr 02, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
accelerated approval and/or priority review for the Biologics License Application ("BLA") of INO-3107 for the treatment of RRP (the "INO-3107 BLA"). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly
More news about: Pomerantz LLP
Apr 02, 2026, 08:55 ET INOVIO Announces Pricing of $17.5 Million Public Offering
PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: INOVIO Pharmaceuticals, Inc.
Apr 01, 2026, 20:05 ET INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: INOVIO Pharmaceuticals, Inc.
Apr 01, 2026, 10:29 ET INOVIO to Participate in Upcoming Scientific Conference
PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer
More news about: INOVIO Pharmaceuticals, Inc.
Apr 01, 2026, 09:00 ET Inovio Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2026 to Discuss Your Rights - INO
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: Levi & Korsinsky, LLP
Mar 31, 2026, 09:00 ET INO Shareholder Alert: April 7, 2026 Lead Plaintiff Deadline in Inovio Pharmaceuticals, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: The Gross Law Firm